The FDA has received reports of two deaths tied to counterfeit versions of retatrutide, an investigational weight-loss medication. The reports were highlighted in a MedPage Today endocrinology roundup, which cited CBS News as the original source. Because retatrutide is not yet approved, any product sold under that name is unregulated, and the deaths underscore the dangers of bootleg weight-loss drugs.
Separately, the roundup notes that ongoing lawsuits allege that GLP-1 receptor agonists can cause severe adverse events. The source does not provide details on those claims, and it does not suggest a direct link between the counterfeit deaths and the lawsuits. The two stories are distinct but together point to heightened scrutiny of the GLP-1 drug class.
The key difference is regulatory status: the counterfeit deaths involve an unapproved, unregulated product, while the lawsuits target approved medications. The source does not indicate whether the counterfeit retatrutide contained an active ingredient or what exactly caused the deaths, only that the FDA was notified.